CCO Annual Update
Hepatitis Annual Update 2007
Epidemiology and Natural History of HBV Infection |
Module 1 of 11 |
|
|
|
Paul Martin, MD, reviews the epidemiology and natural history of HBV infection with particular focus on the differential course of the disease for individuals infected via vertical vs horizontal transmission.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the global patterns of HBV infection and transmission
- Discuss the natural history of chronic HBV infection, including the phases of vertical and horizontal transmission
- Outline what predicts the progression of chronic HBV infection
- Describe the significance of ALT in HBV disease
|
HBV: 2007 Treatment Overview |
Module 2 of 11 |
- Emmet B. Keeffe, MD, MACP
|
|
|
Emmet B. Keeffe, MD, MACP, reviews current hepatitis B virus treatment practices including when to initiate and when to stop therapy, available therapies, and potential future treatment options.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe which patients with chronic hepatitis B virus infection are candidates for therapy
- Summarize clinical data on treatment efficacy of available drugs and duration of therapy
- Discuss development of a treatment plan for monitoring patients while receiving therapy
- Explain when therapy is suboptimal or may lead to the development of resistance
|
A Practical Guide to Management of Patients With Antiviral Drug-Resistant HBV |
Module 3 of 11 |
|
|
|
Anna S. F. Lok, MD, discusses the definitions, consequences of, and treatment strategies for HBV drug resistance.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the clinical consequences of hepatitis B virus (HBV) resistance
- Summarize clinical definitions of resistance and methods for detecting resistance
- Discuss new clinical data on HBV resistance and an algorithm for the management of patients with HBV resistance
|
Treatment of Hepatitis B Virus Infection in Special Populations |
Module 4 of 11 |
|
|
|
Norah Terrault, MD, MPH, discusses the management of hepatitis B virus (HBV) in special populations, including pregnant women, patients undergoing chemotherapy and HIV-infected individuals.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the management of hepatitis B virus (HBV) in pregnancy
- Summarize management of HBV in patients undergoing chemotherapy or treatment with monoclonal antibody therapies
- Describe the interaction of HBV and HIV and implications for therapy
|
Molecular Virology of the Hepatitis C Virus: Implication for Novel Therapies |
Module 5 of 11 |
- Jeffrey S. Glenn, MD, PhD
|
|
|
Jeffrey S. Glenn, MD, PhD, discusses the molecular virology of hepatitis C and its role in the development of novel therapies.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the life cycle of HCV
- List the molecular targets amenable to treatment
- Discuss the biological mechanisms of HCV treatments under development
- Specify the biology of existing treatments for hepatitis C (interferons and ribavirin)
|
Update on New Hepatitis C Virus Therapies |
Module 6 of 11 |
- Jean-Michel Pawlotsky, MD, PhD
|
|
|
Jean-Michel Pawlotsky, MD, PhD, discusses new therapies for hepatitis C virus.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Summarize molecular virology of hepatitis C virus and targets of pharmacologic intervention
- Discuss emerging data on protease/polymerase inhibitor efficacy and other new agents, including vaccines
- Describe the current understanding of resistance mutations with new therapies
- Recount potential future targets of therapy
|
Tailoring Treatment for Hepatitis C: Strategies to Overcome Nonresponse |
Module 7 of 11 |
- Adrian M. Di Bisceglie, MD, FACP
|
|
|
Adrian M. Di Bisceglie, MD, FACP, discusses strategies to overcome nonresponse to treatment for hepatitis C.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the current standard of care for treatment of chronic hepatitis C
- Discuss tailoring of treatment duration and dosing to overcome nonresponse
- Specify other alternatives for treating nonresponders and relapsers
|
Insulin Resistance and Hepatic Steatosis in Patients With Chronic Hepatitis C |
Module 8 of 11 |
- Stephen A. Harrison, MD, FACP
|
|
|
Stephen A. Harrison, MD, LTC, MC, discusses the role of insulin resistance and hepatic steatosis in patients with chronic hepatitis C.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the prevalence of fatty liver and its association with obesity and insulin resistance in patients with chronic hepatitis C
- Summarize the impact of obesity, insulin resistance, and steatosis on the natural history of chronic hepatitis C
- Discuss the outcome of insulin-based therapy in chronic hepatitis C patients with insulin resistance and/or steatosis
|
Growing Pains: Obesity, Bariatric Surgery, and Nonalcoholic Fatty Liver Disease |
Module 9 of 11 |
- Arun J. Sanyal, MBBS, MD, FACP
|
|
|
Arun J. Sanyal, MBBS, MD, FACP, reviews the clinical features of nonalcoholic liver disease and discusses optimal management strategies and emerging treatments for nonalcoholic steatohepatitis.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Cite the clinical features and epidemiology of nonalcoholic fatty liver disease
- Discuss approaches for diagnosing and determining the causes of fatty liver disease in individual patients
- Describe the optimal management of nonalcoholic fatty liver disease and emerging pharmacologic and nonpharmacologic treatments for nonalcoholic steatohepatitis
|
The Epidemic of Hepatocellular Carcinoma: Diagnosis and Therapy |
Module 10 of 11 |
|
|
|
Gary L. Davis, MD, reviews the epidemiology of hepatocelluar carcinoma and provides strategies for the diagnosis and management of this condition.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the changing demographics and epidemiology of hepatocellular carcinoma
- Assess strategies of surveillance for and diagnosis of hepatocellular cancer
- Summarize the various options for management of hepatocellular carcinoma
|
Best of Hepatitis 2007: Top Findings in Viral Hepatitis |
Module 11 of 11 |
|
|
|
Harvey J. Alter, MD, MACP, discusses the top findings in viral hepatitis for the year 2007.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Summarize major findings in viral hepatitis from 2006 and early 2007
- Discuss the broader perspective within which key developments in viral hepatitis should be viewed
- Describe the impact of recent developments in hepatitis on disease management
|
Disclaimer:
The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
|